Generic filters

ANVS – Annovis Bio Inc


The company is Shariah Compliant, according to AAOIFI methodology.

Annovis Bio, Inc. is a clinical-stage drug platform company. The Company is engaged in developing treatments for neurodegenerative diseases, such as Alzheimer’s disease (AD), Parkinson’s disease (PD) and Alzheimer’s disease in Down syndrome (AD-DS). The Company’s lead compound, Buntanetap, is an orally administered drug being developed for chronic indications such as AD, PD and AD-DS. The Company’s ANVS405 compound is being developed for acute indications, focused on protecting the brain after Traumatic brain injury (TBI) and/or stroke. Its ANVS405 is the same compound as Buntanetap, but it is given intravenously in cases of acute head and brain trauma. The Company is also developing its compound, ANVS301 to increase cognitive capability in later stages of AD and dementia.


Debt ÷ Market cap (MC)0
Non-Compliant Assets ÷ MC

Found the Stock You’re Looking For? Open an Account Today!

Opening an account has never been easier! Please fill out the form here and an advisor will be in touch to walk you through the process!

Still have some further questions?